 | • レポートコード：GIR-2104Z07452 • 出版社/出版日：GlobalInfoResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、107ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥487,200 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥730,800 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥974,400 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、免疫チェックポイント阻害剤のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。免疫チェックポイント阻害剤の種類別市場規模（CLTA-4阻害剤、PD-1・PD-L1阻害剤）、用途別市場規模（肺がん、血液がん、腎がん、膀胱がん、黒色腫、ホジキンリンパ腫）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・免疫チェックポイント阻害剤の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Bristol-Myers Squibb Company、AstraZeneca、Merck & Co、Pfizer, Inc、F. Hoffmann-La Roche Ltd、Incyte Corporation、NewLink Genetics Corporation、Celldex Therapeutics, Inc、GlaxoSmithKline、Seattle Genetics, Inc. ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：CLTA-4阻害剤、PD-1・PD-L1阻害剤 ・用途別分析2016年-2026年：肺がん、血液がん、腎がん、膀胱がん、黒色腫、ホジキンリンパ腫 ・免疫チェックポイント阻害剤の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・免疫チェックポイント阻害剤のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・免疫チェックポイント阻害剤のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・免疫チェックポイント阻害剤の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・免疫チェックポイント阻害剤の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Immune Check Point Inhibitors market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Immune Check Point Inhibitors size is estimated to be USD xx million in 2025 from USD xx million in 2019, with a change XX% between 2019 and 2020. The global Immune Check Point Inhibitors market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Immune Check Point Inhibitors market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
CLTA-4 Inhibitors
PD-1 & PD-L1 Inhibitor
Market segment by Application, can be divided into
Lung Cancer
Blood Cancer
Renal Cancer
Bladder Cancer
Melanoma
Hodgkin Lymphoma
Market segment by players, this report covers
Bristol-Myers Squibb Company
AstraZeneca
Merck & Co
Pfizer, Inc
F. Hoffmann-La Roche Ltd
Incyte Corporation
NewLink Genetics Corporation
Celldex Therapeutics, Inc
GlaxoSmithKline
Seattle Genetics, Inc.
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of Immune Check Point Inhibitors
1.2 Classification of Immune Check Point Inhibitors by Type
1.2.1 Overview: Global Immune Check Point Inhibitors Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Immune Check Point Inhibitors Revenue Market Share by Type in 2020
1.2.3 CLTA-4 Inhibitors
1.2.4 PD-1 & PD-L1 Inhibitor
1.3 Global Immune Check Point Inhibitors Market by Application
1.3.1 Overview: Global Immune Check Point Inhibitors Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Lung Cancer
1.3.3 Blood Cancer
1.3.4 Renal Cancer
1.3.5 Bladder Cancer
1.3.6 Melanoma
1.3.7 Hodgkin Lymphoma
1.4 Global Immune Check Point Inhibitors Market Size & Forecast
1.5 Global Immune Check Point Inhibitors Market Size and Forecast by Region
1.5.1 Global Immune Check Point Inhibitors Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Immune Check Point Inhibitors Market Size by Region, (2016-2021)
1.5.3 North America Immune Check Point Inhibitors Market Size and Prospect (2016-2026)
1.5.4 Europe Immune Check Point Inhibitors Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Immune Check Point Inhibitors Market Size and Prospect (2016-2026)
1.5.6 South America Immune Check Point Inhibitors Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Immune Check Point Inhibitors Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Immune Check Point Inhibitors Market Drivers
1.6.2 Immune Check Point Inhibitors Market Restraints
1.6.3 Immune Check Point Inhibitors Trends Analysis
2 Company Profiles
2.1 Bristol-Myers Squibb Company
2.1.1 Bristol-Myers Squibb Company Details
2.1.2 Bristol-Myers Squibb Company Major Business
2.1.3 Bristol-Myers Squibb Company Immune Check Point Inhibitors Product and Solutions
2.1.4 Bristol-Myers Squibb Company Immune Check Point Inhibitors Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Bristol-Myers Squibb Company Recent Developments and Future Plans
2.2 AstraZeneca
2.2.1 AstraZeneca Details
2.2.2 AstraZeneca Major Business
2.2.3 AstraZeneca Immune Check Point Inhibitors Product and Solutions
2.2.4 AstraZeneca Immune Check Point Inhibitors Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 AstraZeneca Recent Developments and Future Plans
2.3 Merck & Co
2.3.1 Merck & Co Details
2.3.2 Merck & Co Major Business
2.3.3 Merck & Co Immune Check Point Inhibitors Product and Solutions
2.3.4 Merck & Co Immune Check Point Inhibitors Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Merck & Co Recent Developments and Future Plans
2.4 Pfizer, Inc
2.4.1 Pfizer, Inc Details
2.4.2 Pfizer, Inc Major Business
2.4.3 Pfizer, Inc Immune Check Point Inhibitors Product and Solutions
2.4.4 Pfizer, Inc Immune Check Point Inhibitors Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Pfizer, Inc Recent Developments and Future Plans
2.5 F. Hoffmann-La Roche Ltd
2.5.1 F. Hoffmann-La Roche Ltd Details
2.5.2 F. Hoffmann-La Roche Ltd Major Business
2.5.3 F. Hoffmann-La Roche Ltd Immune Check Point Inhibitors Product and Solutions
2.5.4 F. Hoffmann-La Roche Ltd Immune Check Point Inhibitors Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 F. Hoffmann-La Roche Ltd Recent Developments and Future Plans
2.6 Incyte Corporation
2.6.1 Incyte Corporation Details
2.6.2 Incyte Corporation Major Business
2.6.3 Incyte Corporation Immune Check Point Inhibitors Product and Solutions
2.6.4 Incyte Corporation Immune Check Point Inhibitors Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Incyte Corporation Recent Developments and Future Plans
2.7 NewLink Genetics Corporation
2.7.1 NewLink Genetics Corporation Details
2.7.2 NewLink Genetics Corporation Major Business
2.7.3 NewLink Genetics Corporation Immune Check Point Inhibitors Product and Solutions
2.7.4 NewLink Genetics Corporation Immune Check Point Inhibitors Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 NewLink Genetics Corporation Recent Developments and Future Plans
2.8 Celldex Therapeutics, Inc
2.8.1 Celldex Therapeutics, Inc Details
2.8.2 Celldex Therapeutics, Inc Major Business
2.8.3 Celldex Therapeutics, Inc Immune Check Point Inhibitors Product and Solutions
2.8.4 Celldex Therapeutics, Inc Immune Check Point Inhibitors Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Celldex Therapeutics, Inc Recent Developments and Future Plans
2.9 GlaxoSmithKline
2.9.1 GlaxoSmithKline Details
2.9.2 GlaxoSmithKline Major Business
2.9.3 GlaxoSmithKline Immune Check Point Inhibitors Product and Solutions
2.9.4 GlaxoSmithKline Immune Check Point Inhibitors Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 GlaxoSmithKline Recent Developments and Future Plans
2.10 Seattle Genetics, Inc.
2.10.1 Seattle Genetics, Inc. Details
2.10.2 Seattle Genetics, Inc. Major Business
2.10.3 Seattle Genetics, Inc. Immune Check Point Inhibitors Product and Solutions
2.10.4 Seattle Genetics, Inc. Immune Check Point Inhibitors Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Seattle Genetics, Inc. Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Immune Check Point Inhibitors Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 5 Immune Check Point Inhibitors Players Market Share
3.2.2 Top 10 Immune Check Point Inhibitors Players Market Share
3.2.3 Market Competition Trend
3.3 Immune Check Point Inhibitors Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Immune Check Point Inhibitors Revenue and Market Share by Type (2016-2021)
4.2 Global Immune Check Point Inhibitors Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Immune Check Point Inhibitors Revenue Market Share by Application (2016-2021)
5.2 Immune Check Point Inhibitors Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Immune Check Point Inhibitors Revenue by Type (2016-2026)
6.2 North America Immune Check Point Inhibitors Revenue by Application (2016-2026)
6.3 North America Immune Check Point Inhibitors Market Size by Country
6.3.1 North America Immune Check Point Inhibitors Revenue by Country (2016-2026)
6.3.2 United States Immune Check Point Inhibitors Market Size and Forecast (2016-2026)
6.3.3 Canada Immune Check Point Inhibitors Market Size and Forecast (2016-2026)
6.3.4 Mexico Immune Check Point Inhibitors Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Immune Check Point Inhibitors Revenue by Type (2016-2026)
7.2 Europe Immune Check Point Inhibitors Revenue by Application (2016-2026)
7.3 Europe Immune Check Point Inhibitors Market Size by Country
7.3.1 Europe Immune Check Point Inhibitors Revenue by Country (2016-2026)
7.3.2 Germany Immune Check Point Inhibitors Market Size and Forecast (2016-2026)
7.3.3 France Immune Check Point Inhibitors Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Immune Check Point Inhibitors Market Size and Forecast (2016-2026)
7.3.5 Russia Immune Check Point Inhibitors Market Size and Forecast (2016-2026)
7.3.6 Italy Immune Check Point Inhibitors Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Immune Check Point Inhibitors Revenue by Type (2016-2026)
8.2 Asia-Pacific Immune Check Point Inhibitors Revenue by Application (2016-2026)
8.3 Asia-Pacific Immune Check Point Inhibitors Market Size by Region
8.3.1 Asia-Pacific Immune Check Point Inhibitors Revenue by Region (2016-2026)
8.3.2 China Immune Check Point Inhibitors Market Size and Forecast (2016-2026)
8.3.3 Japan Immune Check Point Inhibitors Market Size and Forecast (2016-2026)
8.3.4 South Korea Immune Check Point Inhibitors Market Size and Forecast (2016-2026)
8.3.5 India Immune Check Point Inhibitors Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Immune Check Point Inhibitors Market Size and Forecast (2016-2026)
8.3.7 Australia Immune Check Point Inhibitors Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Immune Check Point Inhibitors Revenue by Type (2016-2026)
9.2 South America Immune Check Point Inhibitors Revenue by Application (2016-2026)
9.3 South America Immune Check Point Inhibitors Market Size by Country
9.3.1 South America Immune Check Point Inhibitors Revenue by Country (2016-2026)
9.3.2 Brazil Immune Check Point Inhibitors Market Size and Forecast (2016-2026)
9.3.3 Argentina Immune Check Point Inhibitors Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Immune Check Point Inhibitors Revenue by Type (2016-2026)
10.2 Middle East & Africa Immune Check Point Inhibitors Revenue by Application (2016-2026)
10.3 Middle East & Africa Immune Check Point Inhibitors Market Size by Country
10.3.1 Middle East & Africa Immune Check Point Inhibitors Revenue by Country (2016-2026)
10.3.2 Turkey Immune Check Point Inhibitors Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Immune Check Point Inhibitors Market Size and Forecast (2016-2026)
10.3.4 UAE Immune Check Point Inhibitors Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Immune Check Point Inhibitors Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Immune Check Point Inhibitors Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Immune Check Point Inhibitors Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Immune Check Point Inhibitors Revenue (USD Million) by Region (2016-2021)
Table 5. Global Immune Check Point Inhibitors Revenue Market Share by Region (2021-2026)
Table 6. Bristol-Myers Squibb Company Corporate Information, Head Office, and Major Competitors
Table 7. Bristol-Myers Squibb Company Major Business
Table 8. Bristol-Myers Squibb Company Immune Check Point Inhibitors Product and Solutions
Table 9. Bristol-Myers Squibb Company Immune Check Point Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. AstraZeneca Corporate Information, Head Office, and Major Competitors
Table 11. AstraZeneca Major Business
Table 12. AstraZeneca Immune Check Point Inhibitors Product and Solutions
Table 13. AstraZeneca Immune Check Point Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Merck & Co Corporate Information, Head Office, and Major Competitors
Table 15. Merck & Co Major Business
Table 16. Merck & Co Immune Check Point Inhibitors Product and Solutions
Table 17. Merck & Co Immune Check Point Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Pfizer, Inc Corporate Information, Head Office, and Major Competitors
Table 19. Pfizer, Inc Major Business
Table 20. Pfizer, Inc Immune Check Point Inhibitors Product and Solutions
Table 21. Pfizer, Inc Immune Check Point Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. F. Hoffmann-La Roche Ltd Corporate Information, Head Office, and Major Competitors
Table 23. F. Hoffmann-La Roche Ltd Major Business
Table 24. F. Hoffmann-La Roche Ltd Immune Check Point Inhibitors Product and Solutions
Table 25. F. Hoffmann-La Roche Ltd Immune Check Point Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Incyte Corporation Corporate Information, Head Office, and Major Competitors
Table 27. Incyte Corporation Major Business
Table 28. Incyte Corporation Immune Check Point Inhibitors Product and Solutions
Table 29. Incyte Corporation Immune Check Point Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. NewLink Genetics Corporation Corporate Information, Head Office, and Major Competitors
Table 31. NewLink Genetics Corporation Major Business
Table 32. NewLink Genetics Corporation Immune Check Point Inhibitors Product and Solutions
Table 33. NewLink Genetics Corporation Immune Check Point Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Celldex Therapeutics, Inc Corporate Information, Head Office, and Major Competitors
Table 35. Celldex Therapeutics, Inc Major Business
Table 36. Celldex Therapeutics, Inc Immune Check Point Inhibitors Product and Solutions
Table 37. Celldex Therapeutics, Inc Immune Check Point Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. GlaxoSmithKline Corporate Information, Head Office, and Major Competitors
Table 39. GlaxoSmithKline Major Business
Table 40. GlaxoSmithKline Immune Check Point Inhibitors Product and Solutions
Table 41. GlaxoSmithKline Immune Check Point Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Seattle Genetics, Inc. Corporate Information, Head Office, and Major Competitors
Table 43. Seattle Genetics, Inc. Major Business
Table 44. Seattle Genetics, Inc. Immune Check Point Inhibitors Product and Solutions
Table 45. Seattle Genetics, Inc. Immune Check Point Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Global Immune Check Point Inhibitors Revenue (USD Million) by Players (2019-2021)
Table 47. Global Immune Check Point Inhibitors Revenue Share by Players (2019-2021)
Table 48. Breakdown of Immune Check Point Inhibitors by Company Type (Tier 1, Tier 2 and Tier 3)
Table 49. Immune Check Point Inhibitors Players Head Office, Products and Services Provided
Table 50. Immune Check Point Inhibitors Mergers & Acquisitions in the Past Five Years
Table 51. Immune Check Point Inhibitors New Entrants and Expansion Plans
Table 52. Global Immune Check Point Inhibitors Revenue (USD Million) by Type (2016-2021)
Table 53. Global Immune Check Point Inhibitors Revenue Share by Type (2016-2021)
Table 54. Global Immune Check Point Inhibitors Revenue Forecast by Type (2021-2026)
Table 55. Global Immune Check Point Inhibitors Revenue by Application (2016-2021)
Table 56. Global Immune Check Point Inhibitors Revenue Forecast by Application (2021-2026)
Table 57. North America Immune Check Point Inhibitors Revenue by Type (2016-2021) & (USD Million)
Table 58. North America Immune Check Point Inhibitors Revenue by Type (2021-2026) & (USD Million)
Table 59. North America Immune Check Point Inhibitors Revenue by Application (2016-2021) & (USD Million)
Table 60. North America Immune Check Point Inhibitors Revenue by Application (2021-2026) & (USD Million)
Table 61. North America Immune Check Point Inhibitors Revenue by Country (2016-2021) & (USD Million)
Table 62. North America Immune Check Point Inhibitors Revenue by Country (2021-2026) & (USD Million)
Table 63. Europe Immune Check Point Inhibitors Revenue by Type (2016-2021) & (USD Million)
Table 64. Europe Immune Check Point Inhibitors Revenue by Type (2021-2026) & (USD Million)
Table 65. Europe Immune Check Point Inhibitors Revenue by Application (2016-2021) & (USD Million)
Table 66. Europe Immune Check Point Inhibitors Revenue by Application (2021-2026) & (USD Million)
Table 67. Europe Immune Check Point Inhibitors Revenue by Country (2016-2021) & (USD Million)
Table 68. Europe Immune Check Point Inhibitors Revenue by Country (2021-2026) & (USD Million)
Table 69. Asia-Pacific Immune Check Point Inhibitors Revenue by Type (2016-2021) & (USD Million)
Table 70. Asia-Pacific Immune Check Point Inhibitors Revenue by Type (2021-2026) & (USD Million)
Table 71. Asia-Pacific Immune Check Point Inhibitors Revenue by Application (2016-2021) & (USD Million)
Table 72. Asia-Pacific Immune Check Point Inhibitors Revenue by Application (2021-2026) & (USD Million)
Table 73. Asia-Pacific Immune Check Point Inhibitors Revenue by Region (2016-2021) & (USD Million)
Table 74. Asia-Pacific Immune Check Point Inhibitors Revenue by Region (2021-2026) & (USD Million)
Table 75. South America Immune Check Point Inhibitors Revenue by Type (2016-2021) & (USD Million)
Table 76. South America Immune Check Point Inhibitors Revenue by Type (2021-2026) & (USD Million)
Table 77. South America Immune Check Point Inhibitors Revenue by Application (2016-2021) & (USD Million)
Table 78. South America Immune Check Point Inhibitors Revenue by Application (2021-2026) & (USD Million)
Table 79. South America Immune Check Point Inhibitors Revenue by Country (2016-2021) & (USD Million)
Table 80. South America Immune Check Point Inhibitors Revenue by Country (2021-2026) & (USD Million)
Table 81. Middle East & Africa Immune Check Point Inhibitors Revenue by Type (2016-2021) & (USD Million)
Table 82. Middle East & Africa Immune Check Point Inhibitors Revenue by Type (2021-2026) & (USD Million)
Table 83. Middle East & Africa Immune Check Point Inhibitors Revenue by Application (2016-2021) & (USD Million)
Table 84. Middle East & Africa Immune Check Point Inhibitors Revenue by Application (2021-2026) & (USD Million)
Table 85. Middle East & Africa Immune Check Point Inhibitors Revenue by Country (2016-2021) & (USD Million)
Table 86. Middle East & Africa Immune Check Point Inhibitors Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Immune Check Point Inhibitors Picture
Figure 2. Global Immune Check Point Inhibitors Revenue Market Share by Type in 2020
Figure 3. CLTA-4 Inhibitors
Figure 4. PD-1 & PD-L1 Inhibitor
Figure 5. Immune Check Point Inhibitors Revenue Market Share by Application in 2020
Figure 6. Lung Cancer Picture
Figure 7. Blood Cancer Picture
Figure 8. Renal Cancer Picture
Figure 9. Bladder Cancer Picture
Figure 10. Melanoma Picture
Figure 11. Hodgkin Lymphoma Picture
Figure 12. Global Immune Check Point Inhibitors Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 13. Global Immune Check Point Inhibitors Revenue and Forecast (2016-2026) & (USD Million)
Figure 14. Global Immune Check Point Inhibitors Revenue Market Share by Region (2016-2026)
Figure 15. Global Immune Check Point Inhibitors Revenue Market Share by Region in 2020
Figure 16. North America Immune Check Point Inhibitors Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Europe Immune Check Point Inhibitors Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Asia-Pacific Immune Check Point Inhibitors Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. South America Immune Check Point Inhibitors Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Immune Check Point Inhibitors Market Drivers
Figure 21. Immune Check Point Inhibitors Market Restraints
Figure 22. Immune Check Point Inhibitors Market Trends
Figure 23. Bristol-Myers Squibb Company Recent Developments and Future Plans
Figure 24. AstraZeneca Recent Developments and Future Plans
Figure 25. Merck & Co Recent Developments and Future Plans
Figure 26. Pfizer, Inc Recent Developments and Future Plans
Figure 27. F. Hoffmann-La Roche Ltd Recent Developments and Future Plans
Figure 28. Incyte Corporation Recent Developments and Future Plans
Figure 29. NewLink Genetics Corporation Recent Developments and Future Plans
Figure 30. Celldex Therapeutics, Inc Recent Developments and Future Plans
Figure 31. GlaxoSmithKline Recent Developments and Future Plans
Figure 32. Seattle Genetics, Inc. Recent Developments and Future Plans
Figure 34. Global Immune Check Point Inhibitors Revenue Share by Players in 2020
Figure 35. Immune Check Point Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 36. Global Top 3 Players Immune Check Point Inhibitors Revenue Market Share in 2020
Figure 37. Global Top 10 Players Immune Check Point Inhibitors Revenue Market Share in 2020
Figure 38. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 39. Global Immune Check Point Inhibitors Revenue Share by Type in 2020
Figure 40. Global Immune Check Point Inhibitors Market Share Forecast by Type (2021-2026)
Figure 41. Global Immune Check Point Inhibitors Revenue Share by Application in 2020
Figure 42. Global Immune Check Point Inhibitors Market Share Forecast by Application (2021-2026)
Figure 43. North America Immune Check Point Inhibitors Sales Market Share by Type (2016-2026)
Figure 44. North America Immune Check Point Inhibitors Sales Market Share by Application (2016-2026)
Figure 45. North America Immune Check Point Inhibitors Revenue Market Share by Country (2016-2026)
Figure 46. United States Immune Check Point Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Canada Immune Check Point Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. Mexico Immune Check Point Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. Europe Immune Check Point Inhibitors Sales Market Share by Type (2016-2026)
Figure 50. Europe Immune Check Point Inhibitors Sales Market Share by Application (2016-2026)
Figure 51. Europe Immune Check Point Inhibitors Revenue Market Share by Country (2016-2026)
Figure 52. Germany Immune Check Point Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. France Immune Check Point Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. United Kingdom Immune Check Point Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Russia Immune Check Point Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Italy Immune Check Point Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Asia-Pacific Immune Check Point Inhibitors Sales Market Share by Type (2016-2026)
Figure 58. Asia-Pacific Immune Check Point Inhibitors Sales Market Share by Application (2016-2026)
Figure 59. Asia-Pacific Immune Check Point Inhibitors Revenue Market Share by Region (2016-2026)
Figure 60. China Immune Check Point Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Japan Immune Check Point Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. South Korea Immune Check Point Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. India Immune Check Point Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Southeast Asia Immune Check Point Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Australia Immune Check Point Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. South America Immune Check Point Inhibitors Sales Market Share by Type (2016-2026)
Figure 67. South America Immune Check Point Inhibitors Sales Market Share by Application (2016-2026)
Figure 68. South America Immune Check Point Inhibitors Revenue Market Share by Country (2016-2026)
Figure 69. Brazil Immune Check Point Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Argentina Immune Check Point Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Middle East and Africa Immune Check Point Inhibitors Sales Market Share by Type (2016-2026)
Figure 72. Middle East and Africa Immune Check Point Inhibitors Sales Market Share by Application (2016-2026)
Figure 73. Middle East and Africa Immune Check Point Inhibitors Revenue Market Share by Country (2016-2026)
Figure 74. Turkey Immune Check Point Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. Saudi Arabia Immune Check Point Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. UAE Immune Check Point Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Methodology
Figure 78. Research Process and Data Source
世界の次世代パワー半導体市場規模・現状・予測（2021年-2027年） Silicon semiconductor products have evolved over time, with the creation of high precision semiconductor manufacturing equipments and the optimization of device configuration and wafer process. This contributed to the development of miniaturized and high performance electronic products which have be…- 世界のTNF阻害剤市場規模・現状・予測（2021年-2027年） TNF (tumor necrosis factor) inhibitors are anti-inflammatory drugs. TNF inhibitors help to block the TNF alpha that occurs naturally in the body and causes inflammation. TNF drugs are used to reduce inflammation and stop disease progression by targeting the tumor necrosis factor, which is an inflamm…
- 世界のシグナル伝達阻害剤市場規模・現状・予測（2021年-2027年） Signal transduction inhibitors are drugs that may prevent the ability of cancer cells to multiply quickly and invade other tissues. Growing need for effective cancer diagnostics and innovative therapies for cancer treatment are expected to be the major factors driving the signal transduction inhibit…
- 世界の免疫レパートリーシーケンシング市場規模・現状・予測（2021年-2027年） Immune Repertoire is the collection of B and T cells with functional diversity in the body that reflects the immune selectivity. Immune Repertoire Sequencing means to sequence the complimentary determining region of both B-cell receptor and T-cell receptor. Immune receptor repertoire profiling portr…
- 世界のファイアウォール装置市場 2021：企業別、地域別、種類・用途別 The Firewall Devices market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, r…